高手术风险急性胆囊炎患者经皮胆囊造瘘术后的管理:国际德尔菲共识研究结果
该研究由意大利外科研究学会(SIRC)与意大利急诊外科与创伤学会(SICUT)组织国际及意大利专家,经针对性文献回顾后用德尔菲法形成10条声明,旨在提出高手术风险急性胆囊炎患者经皮胆囊造瘘(PC)的指征及胆囊引流管理策略(作为手术桥接或 definitive 治疗)。共识明确:中度急性胆囊炎、Charlson合并症指数(CCI)≥6、美国麻醉医师协会体能状态(ASA-PS)≥3且保守治疗失败者,首选腹腔镜胆囊切除术;高手术风险重度急性胆囊炎推荐PC在24-48小时内缓解症状;感染控制后评估 interval 腹腔镜胆囊切除术候选者,选择手术者推荐PC置入至少6周后行腹腔镜胆囊切除术;不适合手术者(如CCI≥6且ASA-PS≥4)PC应留置至少3周,影像学确认胆道通畅后可拔管。该共识由介入放射科、消化科和外科多学科协作制定,为高危手术急性胆囊炎患者管理提供清晰实用的指导。
要点
- 中度急性胆囊炎、CCI≥6、ASA-PS≥3且保守治疗失败者,共识推荐首选腹腔镜胆囊切除术。
- 高手术风险重度急性胆囊炎,推荐经皮胆囊造瘘(PC)在24-48小时内缓解症状。
- 感染控制后应评估 interval 腹腔镜胆囊切除术候选者;选择手术者推荐PC置入至少6周后行腹腔镜胆囊切除术。
- 不适合手术者(如CCI≥6且ASA-PS≥4),PC应留置至少3周,影像学确认胆道通畅后可拔管。
适用人群与场景
- 高手术风险的中重度急性胆囊炎患者;中度患者需CCI≥6且ASA-PS≥3且保守治疗失败;重度患者为高手术风险;不适合手术者如CCI≥6且ASA-PS≥4。
诊断标准与关键阈值
- Charlson合并症指数(CCI)≥6且美国麻醉医师协会体能状态(ASA-PS)≥3用于界定中度急性胆囊炎高手术风险人群。
- CCI≥6且ASA-PS≥4用于界定不适合手术、PC作为 definitive 治疗的人群。
处置流程与药物剂量
- 中度急性胆囊炎、CCI≥6、ASA-PS≥3且保守治疗失败者:首选腹腔镜胆囊切除术。
- 高手术风险重度急性胆囊炎:推荐经皮胆囊造瘘(PC)在24-48小时内缓解症状。
- PC后感染控制:评估哪些患者可能成为 interval 腹腔镜胆囊切除术候选者。
- 选择手术者:推荐PC置入至少6周后行腹腔镜胆囊切除术。
- 不适合手术者(如CCI≥6且ASA-PS≥4):PC应留置至少3周,之后影像学确认胆道通畅,可拔管。
研究设计与关键结果
- 该研究为国际德尔菲共识研究,由意大利外科研究学会(SIRC)与意大利急诊外科与创伤学会(SICUT)组织国际及意大利专家,经针对性文献回顾后以德尔菲法形成10条声明,最终达成共识。
证据类型、等级与局限
- 证据类型:国际德尔菲共识研究;证据等级:德尔菲共识声明。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对高手术风险中度急性胆囊炎(CCI≥6、ASA-PS≥3)且保守治疗失败者,共识推荐首选腹腔镜胆囊切除术,而非直接PC。
- 对高手术风险重度急性胆囊炎,共识推荐PC在24-48小时内缓解症状,不应延迟引流。
- PC后感染控制后需评估 interval 腹腔镜胆囊切除术候选者;选择手术者推荐PC置入至少6周后手术,不适合手术者(CCI≥6且ASA-PS≥4)PC留置至少3周并在影像学确认胆道通畅后拔管。
指南或共识出处
- 国际德尔菲共识研究(Int J Surg),由意大利外科研究学会(SIRC)与意大利急诊外科与创伤学会(SICUT)组织。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: The management of high-surgical-risk patients with moderate to severe acute cholecystitis is challenging in clinical practice. Early laparoscopic cholecystectomy is considered the gold standard for patients who do not respond to conservative treatment. However, for those unfit for surgery due to high risk, alternative treatment options, such as percutaneous cholecystostomy (PC), are available. There are no clear guidelines regarding the management of patients following PC. The primary aim of this study was to propose indications for PC in high-surgical-risk patients with acute cholecystitis and to establish management strategies for gallbladder drainage, either as a bridge to surgery or as a definitive treatment, according to available literature.
MATERIALS AND METHODS: After a targeted literature review, International and Italian experts in the field from the Italian Society of Research in Surgery (SIRC) and the Italian Society of Emergency Surgery and Trauma (SICUT) were consulted to provide their evidence-based opinions on the topic. Statements were proposed during subsequent rounds using the Delphi methodology. Ten statements were provided, and the final agreement is presented in this study.
RESULTS: Patients with moderate acute cholecystitis, a Charlson Comorbidity Index (CCI) ≥ 6, and American Society of Anesthesiologists-Performance Status (ASA-PS) ≥ 3 who fail conservative treatment should undergo laparoscopic cholecystectomy as the first-line approach. For those with severe acute cholecystitis at high-surgical risk, percutaneous cholecystostomy is recommended to relieve symptoms within 24-48 hours. Once the infection is controlled, we should assess which patients may be candidates for interval laparoscopic cholecystectomy. For patients selected for surgery, laparoscopic cholecystectomy is recommended at least six weeks after PC placement. In patients not suitable for surgery, such as those with CCI ≥ 6 and ASA-PS ≥ 4, percutaneous cholecystostomy should remain in place for at least three weeks, after which, following radiographic confirmation of biliary tree patency, the tube may be removed.
CONCLUSIONS: This consensus, developed through a multidisciplinary collaboration of interventional radiologists, gastroenterologists, and surgeons, provides a clear and practical guide for managing high-risk surgical patients with acute cholecystitis.
参考来源
- Pesce A, Ramírez-Giraldo C, Arkoudis NA, et al. Management of high-surgical-risk patients with acute cholecystitis following percutaneous cholecystostomy: results of an international Delphi consensus study. Int J Surg. 2025. PMID: 40072363. doi:10.1097/JS9.0000000000002325
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。